- Home
- PCYO vs GALT Comparison
PCYO vs GALT Comparison
Compare PCYO & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- GALT
- Stock Information
- Founded
- PCYO 1976
- GALT 2000
- Country
- PCYO United States
- GALT United States
- Employees
- PCYO N/A
- GALT N/A
- Industry
- PCYO Water Supply
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- PCYO Utilities
- GALT Health Care
- Exchange
- PCYO Nasdaq
- GALT Nasdaq
- Market Cap
- PCYO 242.7M
- GALT 232.3M
- IPO Year
- PCYO N/A
- GALT N/A
- Fundamental
- Price
- PCYO $10.13
- GALT $3.57
- Analyst Decision
- PCYO
- GALT Strong Buy
- Analyst Count
- PCYO 0
- GALT 3
- Target Price
- PCYO N/A
- GALT $6.00
- AVG Volume (30 Days)
- PCYO 42.1K
- GALT 292.3K
- Earning Date
- PCYO 07-09-2025
- GALT 08-14-2025
- Dividend Yield
- PCYO N/A
- GALT N/A
- EPS Growth
- PCYO 123.89
- GALT N/A
- EPS
- PCYO 0.56
- GALT N/A
- Revenue
- PCYO $27,447,000.00
- GALT N/A
- Revenue This Year
- PCYO N/A
- GALT N/A
- Revenue Next Year
- PCYO N/A
- GALT N/A
- P/E Ratio
- PCYO $17.93
- GALT N/A
- Revenue Growth
- PCYO 40.36
- GALT N/A
- 52 Week Low
- PCYO $9.65
- GALT $0.73
- 52 Week High
- PCYO $14.63
- GALT $4.41
- Technical
- Relative Strength Index (RSI)
- PCYO 50.97
- GALT 58.06
- Support Level
- PCYO $9.80
- GALT $3.55
- Resistance Level
- PCYO $10.48
- GALT $3.90
- Average True Range (ATR)
- PCYO 0.22
- GALT 0.32
- MACD
- PCYO 0.05
- GALT -0.04
- Stochastic Oscillator
- PCYO 57.83
- GALT 41.67
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.